Follicular Lymphoma
Conference Coverage
Basiliximab/BEAM may improve post-ASCT outcomes in PTCL
LA JOLLA, CALIF. – The phase 1 trial is testing the use of a CD25 monoclonal antibody for achieving long-term remission in PTCL.
News
Assay identifies actionable mutations in lymphoid malignancies
Researchers say hybrid capture sequencing is an accurate and sensitive method for identifying actionable gene mutations in lymphoid malignancies....
Conference Coverage
Combo is preferentially active in T-cell lymphomas
LA JOLLA, CA—A 2-drug combination has demonstrated preferential activity in T-cell lymphomas over B-cell lymphomas, according to researchers. In a...
Conference Coverage
TRANSCEND NHL trial identifies window
for CAR T expansion
SAN FRANCISCO – The study shows a correlation between certain patient characteristics and outcomes with the CAR T-cell therapy JCAR017.
Conference Coverage
BTK inhibitor zanubrutinib active in non-Hodgkin lymphomas
ATLANTA – Response rates ranged from 31% to 88% depending on the lymphoma subtype.
News
Update reveals ongoing responses in ZUMA-1
ATLANTA—The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel; KTE-C19) is showing consistent, ongoing responses...
Conference Coverage
Risk stratification may be possible with JCAR017
ATLANTA—Data suggest a therapeutic window may exist for chimeric antigen receptor (CAR) T-cell expansion with JCAR017, according to a preliminary...
Article
Cancer care in 2017: the promise of more cures with the challenges of an unstable health care system
Conference Coverage
Primary analysis confirms interim findings of CTL019 in DLBCL
ATLANTA—The first chimeric antigen receptor (CAR) T-cell therapy approved in the US to treat children and young adults with leukemia is also...
Conference Coverage
VIDEO - New lymphoma drug approvals: Clinical use, future directions
ATLANTA - At the ASH annual meeting, FDA representatives and clinicians discussed new lymphoma drug approvals and their use in the real-world...